Biosimilars

August 16, 2022

Disease flareups occurred in seven women who stopped biosimilar treatment and two who continued without stopping, according to findings published in the journal Obstetric Medicine.

August 03, 2022

Humira may face competition from multiple generics next year, but an octet of other biologics may also see competition this decade.

July 19, 2022

Metaphors of brewing beer and other concepts may help overcome some of the reluctance to prescribing biosimilars.

July 18, 2022

But the out-of-pocket costs were 47% to 59% lower for patients treated with received the biosimilars Fulphia and Udenyca as primary prophylaxis for febrile neutropenia.

July 14, 2022

Price may also be persuasive. The price of the biosimilar is expected to be about 9% lower than its reference product, Lucentis.

June 06, 2022

If biosimilar acceptance is to grow, it’s going to take a great deal of work to improve the levels of trust between payers, patients, and oncologists.

June 03, 2022

The review, partly funded by Amgen, the maker of Riabni, makes the case for using the biosimilar to Rituxan for all indications of the originator.

June 02, 2022

The average sales price (ASP) for biosimilars of Neupogen has declined more than 50% since these lower cost agents began to be sold in 2015.

May 29, 2022

Pharmacy benefit managers can help health plans understand when to best leverage and align to biosimilars and other cost-effective treatments, argues Prime Therapeutics' Kelly McGrail-Pokuta.

May 19, 2022

Circle 2023 on your calendar. That's when as many as 11 biosimilars to Humira are headed for the U.S. market.